[Development of a new tubulin-interacting agent, docetaxel (taxotere) in Japan].
A new semi-synthetic taxoid, docetaxel (taxotere) was recently developed in Japan. The phase I study was initiated in 1991, and the MTD was determined as 70-90 mg/m2, dose-limiting factor as leukopenia, and recommended dose for the phase II study as 60 mg/m2, every 3-4 weeks. The early and late phase II studies were conducted based on above dose schedule. After the late phase II studies, appreciable responses were obtained against advanced recurrent breast (50.4%) and inoperable lung (22.4%) cancers, and the results were accepted by MHW of the Japanese Government. Docetaxel possesses an unique tubulin-interacting activity (promotion of assembly of stable microtubules) and currently combination studies with other anticancer drugs or radiotherapy are ongoing.
Tsukagoshi
S
S
Cancer Institute, Japanese Foundation for Cancer Research.
D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D004357:Drug Synergism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D043823:Taxoids; D014404:Tubulin / Q000494:pharmacology
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D014404:Tubulin; D000077143:Docetaxel; D017239:Paclitaxel